In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Warner Chilcott gets US rights to Novartis' Enablex

Executive Summary

Novartis AG has granted Warner Chilcott PLC (primarily dermatology, women's health, gastrointestinal, and muscloskeletal conditions) exclusive US marketing rights to Enablex (darifenacin) extended-release tablets for adults with symptoms of an overactive bladder, which include urge urinary incontinence, urgency, and frequency.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Marketing (Licensing)

Related Companies